• | an identification of the general safety and performance requirements that require support from relevant clinical data; | |
• | an identification of the GSPR that require support from relevant clinical data. | |
• | a specification of the intended purpose of the device; | |
• | a specification of the intended purpose of the device. | |
• | a clear specification of intended target groups with clear indications and contra-indications; | |
• | a clear specification of intended target groups with clear indications and contraindications. | |
• | a detailed description of intended clinical benefits to patients with relevant and specified clinical outcome parameters; | |
• | a detailed description of intended clinical benefits to patients with relevant and specified clinical outcome parameters. | |
|
• | a strategy to identify, analyse and assess alternative treatments | |
• | a specification of methods to be used for examination of qualitative and quantitative aspects of clinical safety with clear reference to the determination of residual risks and side-effects; | |
• | a specification of methods to be used for examination of qualitative and quantitative aspects of clinical safety with clear reference to the determination of residual risks and side-effects; | |
• | an indicative list and specification of parameters to be used to determine, based on the state of the art in medicine, the acceptability of the benefit-risk ratio for the various indications and for the intended purpose or purposes of the device; | |
• | an indicative list and specification of parameters to be used to determine, based on the state of the art in medicine, the acceptability of the benefit-risk ratio for the various indications and for the intended purpose or purposes of the device. | |
• | an indication how benefit-risk issues relating to specific components such as use of pharmaceutical, non-viable animal or human tissues, are to be addressed | |
• | an indication how benefit-risk issues relating to specific components such as use of pharmaceutical, non- viable animal or human tissues, are to be addressed | |
|
• | a strategy and methodology to identify, analyse and appraise all relevant available clinical data in light of the changed definition for clinical data. | |
|
• | evidence for equivalence, if clinical data from an equivalent device is included in the clinical evaluation. | |
|
• | a definition of the required level of clinical evidence, which shall be appropriate in view of the characteristics of the device and its intended purpose (Hier sei auf die Fußnote 60 der MDCG 2020-6 hingewiesen, die fordert: „and a clinical assessment of failure modes associated with the device”. Diese Forderung stellt die Autoren der klinischen Bewertung vor große Herausforderungen, denn sie setzt ein Verständnis des Begriffs „failure mode” aus dem Risikomanagement voraus. Auch ist es eine klassische Aufgabe des Risikomanagements, das Versagen eines Gerätes oder einer Funktion zu untersuchen.) | |
|
• | a strategy and methodology to systematically collect, summarise and assess post market surveillance data to demonstrate continuing safety and performance, and to what extent complaints with regards to safety and performance have been observed with the legacy devices. | |
• | a clinical development plan indicating progression from exploratory investigations, such as first-in-man studies, feasibility and pilot studies, to confirmatory investigations, such as pivotal clinical investigations, and a PMCF as referred to in Part B of this Annex with an indication of milestones and a description of potential acceptance criteria; | | |